Genomic Landscape, Characteristics, and Clinical Outcomes of TP53-Mutated Therapy-Related Myeloid Neoplasms
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
Blood Cancer J 2023 Apr 11;13(1)51, MV Shah, ENH Tran, S Shah, R Chhetri, A Baranwal, D Ladon, C Shultz, A Al-Kali, AL Brown, D Chen, HS Scott, P Greipp, D Thomas, HB Alkhateeb, D Singhal, N Gangat, S Kumar, MM Patnaik, CN Hahn, CH Kok, A Tefferi, DK HiwaseFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.